scholarly journals DOUBLING OF THE CARDIAC RHYTHM AND ITS RELATION TO PAROXYSMAL TACHYCARDIA.

1906 ◽  
Vol XLVI (13) ◽  
pp. 941 ◽  
Author(s):  
ALBION WALTER HEWLETT
2020 ◽  
Vol 24 (1-2) ◽  
pp. 24-29
Author(s):  
R.V. Lutsenko ◽  
Yu. A. Kapustnick ◽  
A. H. Sydorenko

The aim of the research was to analyze the possibility of using different antiarrhythmic agents in patients with pre-excitation syndrome and disorders of cardiac rhythm. Most typical disorders of cardiac rhythm in patients with pre-excitation syndrome are orthodromic reciprocating supraventricular tachycardia, antidromic supraventricular tachycardia, atrial fibrillation and atrial fibrillation. During attack of tachycardia in patients with syndrome of pre-excitation, different clinical symptoms can be observed. They can range from mild palpitation to syncope. This tachycardia can be even reason of sudden cardiac death. Main its mechanism is macroreentrant circuit involving the AV-node, the additional pathway, the atria, the ventricles. To arrest the attacks of atrioventricular reciprocating tachycardia in patients with WPW syndrome and with narrow complexes QRS, calcium channel blocker verapamil has efficacy in 95% of patients. However, for treatment this arrhythmia with wide complexes QRS verapamil is contraindicated. Besides, it should be taken in account that treatment with this type of cardiac arrhythmia cardiac glycosides is also forbidden. Verapamil and cardiac glycosides are contraindicated for termination of arrhythmia in patients with WPW syndrome and such disorders of cardiac rhythm as atrial fibrillation (flutter). For therapy of atrial fibrillation (flutter) in patients with WPW syndrome antiarrhythmic agents of agents of І A subclass (quinidine, procainamide, disopyramide, propafenone) and ІІІ class (amiodarone, sotalol) can be useful. For interruption of paroxysmal tachycardia in patients with pre-excitation syndrome antiarrhythmical preparations of plant origin (gilurytmal and allapinin) have high efficacy. Termination of paroxysmal tachycardia in patients with premature excitation of ventricles can be achieved after administration of antiarrhythmic agents of ІС subclass, in particular after using of propafenone and encainide. However, treatment with the help of these agents quite often leads to appearance of arrhythmogenic action. In pre-excitation syndrome and cardiac arrhythmias, it is impossible to use drugs, which cause the acceleration of conductivity of nerve impulses in additional pathways (cardiac glycosides, β-blocker agents, for example propranolol). In patients with paroxysmal atrioventricular reciprocating (circular) tachycardia digitalis and calcium channel blockers should be avoided. Such agents as digoxin and verapamil in this arrhythmia can turn out to be dangerous in WPW syndrome, since they raise the conductivity through additional conductive pathways.


1966 ◽  
Vol 210 (3) ◽  
pp. 505-508 ◽  
Author(s):  
AL Pinkerson ◽  
MH Luria ◽  
ED Freis
Keyword(s):  

Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S112
Author(s):  
Robert Przybylski ◽  
Molly Craig ◽  
Matthew Lippmann ◽  
Douglas Y. Mah ◽  
John K. Triedman ◽  
...  
Keyword(s):  

2021 ◽  
Vol 147 ◽  
pp. 110942
Author(s):  
Diana J. Templos-Hernández ◽  
Luis A. Quezada-Téllez ◽  
Brian M. González-Hernández ◽  
Gerardo Rojas-Vite ◽  
José E. Pineda-Sánchez ◽  
...  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Guedeney ◽  
J Silvain ◽  
F Hidden-Lucet ◽  
C Maupain ◽  
S Dinanian ◽  
...  

Abstract Background There are only limited options for long-term cardiac monitoring devices readily available in clinical practice for outpatients. Holter monitoring devices are limited by the uncomfort of wires and patches, the small number of leads for analysis, the quality of recordings or the monitoring duration while insertable cardiac monitors are costly and exposed to potential local complication. Purpose To describe a single center experience with a novel wearable device for cardiac rhythm monitoring. Methods The Cardioskin™ system is a patch-free, wire-free, wearable device with rechargeable batteries that provides a high quality 15-lead electrocardiogram monitoring over 1 month (Figure 1). Data are sent using a mobile application downloaded in the patient smartphone to a central Corelab where they can be interpreted by an expert and/or the prescribing physician. An alarm signal is readily available within the Cardioskin™ device, to allow patients to indicate the presence of symptoms. In this single center retrospective registry, we provide a first report of the use of this novel device in real world practice, with indication and duration of cardiac monitoring left at the physicans “discretion”. Results From January 2019 to December 2019, the Cardioskin™ system was prescribed in 60 patients for an overall median duration of 26.5 (14–32) days. The mean age of the patients was 45±12.2 years and 24 (40%) were male. Indications for cardiac monitoring were post-Stroke, palpitation, syncope and cardiomyopathy assessment in 56%, 30%, 7% and 7% of the cases, respectively. A sustained (>30 seconds) supraventricular tachycardia was detected in 4 cases, including one case of atrial fibrillation, two case of atrial tachycardia and on case of junctional tachycardia. Unsustained ventricular tachycardia and atrial fibrillation burst were detected in another 2 cases (Figure 1). There was no reported case of skin irritation by the Cardioskin™ system or abrupt interruption of the monitoring by the patients. Conclusion The Cardioskin™ system is a novel, discreet and comfortable cardiac rhythm wearable long-term monitoring device which can be used in clinical practice for broad diagnostic indications. Figure 1. Cardioskin system Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): ACTION coeur


Sign in / Sign up

Export Citation Format

Share Document